Equillium (STU:0FY) Marketable Securities : €19.06 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Equillium Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Equillium's Marketable Securities for the quarter that ended in Mar. 2024 was €19.06 Mil.

Equillium's annual Marketable Securities declined from Dec. 2021 (€26.86 Mil) to Dec. 2022 (€11.25 Mil) but then increased from Dec. 2022 (€11.25 Mil) to Dec. 2023 (€16.19 Mil).

Equillium Marketable Securities Historical Data

The historical data trend for Equillium's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Marketable Securities Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

35.93

47.83

26.86

11.25

16.19

Equillium Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Marketable Securities	Get a 7-Day Free Trial															35.02	21.00	11.17	16.19	19.06

Equillium Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Equillium (STU:0FY) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Equillium Marketable Securities Related Terms

Thank you for viewing the detailed overview of Equillium's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium (STU:0FY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (STU:0FY) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

EQ:USA

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium (STU:0FY) Headlines

No Headlines